{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CLL%2FSLL+SoC", "query": { "intervention": "CLL/SLL SoC" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 5, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T12:10:51.140Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07108998", "title": "Study of Epcoritamab as a Consolidation Therapy in CLL/SLL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CLL/SLL", "CLL", "SLL", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Small Lymphocytic Lymphoma Variant", "Chronic Lymphocytic Leukemia Variants" ], "interventions": [ { "name": "Epcoritamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zulfa Omer", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2025-08-22", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-09-04T12:10:51.140Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07108998" }, { "nct_id": "NCT07572006", "title": "A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "JNJ-95804306", "type": "DRUG" }, { "name": "AML SoC", "type": "DRUG" }, { "name": "CLL/SLL SoC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2026-05-13", "completion_date": "2032-09-24", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-04T12:10:51.140Z", "location_count": 6, "location_summary": "Indianapolis, Indiana • Grand Rapids, Michigan • Piscataway, New Jersey + 3 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Piscataway", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07572006" }, { "nct_id": "NCT07734038", "title": "Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Kerry Rogers", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2026-10-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-04T12:10:51.140Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07734038" }, { "nct_id": "NCT00691015", "title": "Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "total body irradiation (TBI)", "type": "RADIATION" }, { "name": "anti-thymocyte globulin IV", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2008-05", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2017-06-28", "last_synced_at": "2026-09-04T12:10:51.140Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00691015" }, { "nct_id": "NCT07194980", "title": "Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Nemtabrutinib", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-09-01", "completion_date": "2029-10-20", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-04T12:10:51.140Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07194980" } ] }